Key Highlights

  • Audeara's FY26 Revenue rose 17.5 per cent to A$4.45 million and its statutory loss narrowed to A$1.30 million.
  • Auditor Grant Thornton included an emphasis of matter on a going-concern material uncertainty.
  • After year end the company announced a A$1.26 million Placement at A$0.033 per share.

Audeara (ASX:AUA), a hearing-health technology company based in Bowen Hills, Queensland, grew revenue in FY26 while still reporting a going-concern material uncertainty. Its FY26 annual report, signed on 31 August 2026, showed revenue of A$4.45 million, up 17.5 per cent, and a smaller statutory loss of A$1.30 million. Even so, the auditor, Grant Thornton, included an emphasis of matter on the uncertainty, and the company announced a A$1.26 million placement on 21 August 2026.

Business and revenue mix

Audeara develops personalised hearing and audio technology. It sells hearing products through Australian wholesale customers and earns engineering and licensing income through its AUA Technology arm. In FY26, Australian wholesale revenue rose about 45 per cent to A$2.62 million.

The Annual Report lists a chip-level AI audio agreement with OPTEK Microelectronics; a hearing-aid licensing programme in China with Eastech, whose first order covered 1,000 licence keys; additional white-label programmes with Clinico in Taiwan, with introductory orders of about A$164,000; and an Auracast rollout with Bolton Clarke across 43 retirement villages.

Not all of these agreements are generating revenue yet. In its January 2026 quarterly report, the company said no revenue had been recognised from the OPTEK agreement because customer programmes had not reached purchase orders, and in April 2026 it said its China partner was reviewing its go-to-market strategy, which was delaying traction. Management's stated priorities are converting partner programmes into production revenue and reaching sustainable positive operating cash flow.

Cash flow through the year

Audeara reported positive Operating Cash Flow of about A$356,000 in the December 2025 quarter, helped by a A$1.22 million R&D tax refund, and A$359,000 in the March 2026 quarter, when cash rose to A$1.05 million. Revenue in the March quarter was A$1.0 million, compared with about A$1.43 million in each of the two preceding quarters. By 30 June 2026, cash had fallen to A$0.74 million from A$1.42 million a year earlier. Net operating cash flow for the year was about negative A$0.39 million, an improvement on FY25. Simple arithmetic on the reported figures, subtracting year-to-date revenue of A$3.9 million to March from the full-year total, implies roughly A$0.55 million of revenue in the June quarter.

Balance sheet, Debt and funding

Net Assets fell to A$0.18 million from A$1.29 million, and current liabilities of A$3.02 million exceeded current assets of A$2.92 million. R&D spending was A$3.04 million, with a tax incentive refund of about A$1.32 million expected. At 31 March 2026, a short-term Loan from Sturt Capital, secured against the expected rebate, had A$417,876 owing at 1.33 per cent monthly interest, due by the earlier of receipt of the rebate or 31 December 2026. The largest customer accounted for about 35 per cent of revenue and the top four for about 78 per cent.

The August placement

After year end, Audeara announced a A$1.26 million placement at A$0.033 per share, with the second Tranche requiring Shareholder approval. Dividing the placement amount by the issue price gives roughly 38 million new shares, so the raising dilutes existing holders. The directors cite cost reductions, the R&D incentive, customer orders and cash reserves as grounds for continuing as a going concern.

Risks

The main risks are the going-concern uncertainty, customer concentration, dependence on partners converting programmes into orders, and distribution risk in markets such as China.

The Bottomline

Audeara's FY26 accounts show growing wholesale revenue and a narrower loss, alongside thin net assets, a working Capital Deficit and reliance on an R&D refund and a placement to fund operations. Management has identified the conversion of partner programmes such as those with OPTEK, Eastech and Clinico into production revenue as its main operational priority.